InvestorsHub Logo
Followers 608
Posts 42247
Boards Moderated 6
Alias Born 01/10/2004

Re: pinkslipjunkie post# 230

Sunday, 09/12/2010 11:52:06 PM

Sunday, September 12, 2010 11:52:06 PM

Post# of 38310
TRDX CHART 0.0195








TRDX Announces Completion of Key Milestone and Provides Details on Closing of Definitive Agreement With Genesis Biopharma, Inc.

Friday , September 10, 2010 16:30ET

http://www.knobias.com/story.htm?eid=3.1.f8e2d67505bd21745d8bcb98830cfb17f362430e3ae9f774836592c8555fadb8

http://www.knobias.com/individual/public/quote.htm?ticker=TRDX

http://www.otcmarkets.com/stock/TRDX/company-info

http://www.barchart.com/detailedquote/stocks/TRDX

http://www.genesisbiopharma.com/newsandevents.html

JERICHO, NY -- (Marketwire) -- 09/10/10 -- SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. ("DiabetRX") which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.

In addition, the Company provides the following details regarding the recently executed Definitive Sublicense Agreement ("Definitive") with Montreal-based Genesis Biopharma, Inc. ("Genesis").

General Terms:

Financing TRDX has committed to a financing of $800,000 for the
continued R&D of Genesis' Painful Diabetic Neurapathy
("PDN") solution

The financing can be completed in tranches, with each
tranche resulting in a pro-rated ownership of DiabetRX.

First Tranche $60,000 required to maintain sublicense and take possession
of the first 7.5% of DiabetRX

Initial Closing The Initial Closing is based on, amongst other items, the
completion of customary due diligence by the parties

Final Closing Final Closing is defined as the completion of the $800,000
financing for the development of the PDN solution

Dr. Jan Stahl, CEO of TRDX, commented: "Since the signing of the Definitive Agreement, I am very happy with the progress we have made with Genesis. We feel confident in the current steps we are taking to complete the Initial Closing and first Tranche financing. We view DiabetRX as a long term investment with large potential and look forward to the Final Closing."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (http://www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact:
SciMeDent Health Corp. f/k/a Trend Exploration, Inc.
dmyers@cadenceconsultingllc.com
1-866-383-1374


Source: Trend Exploration, Inc.


Public Companies Associated with this story:
TRDX

Knobias Subject Codes Associated with this story:
Corp Financing Important Co. News Major Agreements Management Issues
Merger/Acquisition Patent/Trademark Product News Regulators
Shareholder Issues

Content provided by Market Wire Copyright © 2010
Content transmitted by Knobias.com Copyright © 2010 Visit Knobias.com

http://www.knobias.com/story.htm?eid=3.1.f8e2d67505bd21745d8bcb98830cfb17f362430e3ae9f774836592c8555fadb8

http://www.knobias.com/individual/public/quote.htm?ticker=TRDX

http://www.otcmarkets.com/stock/TRDX/company-info

http://www.barchart.com/detailedquote/stocks/TRDX

http://www.genesisbiopharma.com/newsandevents.html









ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2010 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

Stop By And Visit Me At The SmallCap Trading Techniques Board

http://investorshub.advfn.com/boards/board.aspx?board_id=4203

Valuable Trading Ideas to help you make more MOMO!

http://investorshub.advfn.com/boards/board.aspx?board_id=4203